论文部分内容阅读
目的观察小剂量尿激酶治疗进展性脑梗死的疗效。方法将62例进展性脑梗死患者随机分为2组,25万组和50万组。25万组给予尿激酶25万U加人100ml0.9%氯化钠注射液静脉滴注,50万组给予尿激酶50万单位加人100ml0.9%氯化钠注射液静脉滴注,两组均给予抗血小板聚集、抗凝、活血化瘀、改善微循环等药物治疗。对2组治疗前、治疗后24h、治疗后14d进行四肢肌力分级。结果治疗后24h,2组四肢肌力之和比较差异有统计学意义(P<0.05),50万组明显高于25万组。且2组均无出血病例。结论 50万U尿激酶治疗进展性脑梗死安全、可能有效。
Objective To observe the therapeutic effect of low-dose urokinase on patients with progressive cerebral infarction. Methods 62 patients with progressive cerebral infarction were randomly divided into two groups, 250,000 and 500,000 groups. 250000 group given urokinase 250000 U plus 100ml0.9% sodium chloride injection intravenous infusion, 500000 group given urokinase 500000 units plus 100ml0.9% sodium chloride injection intravenous infusion, two groups Are given anti-platelet aggregation, anticoagulant, blood circulation, improve microcirculation and other drug treatment. The two groups before treatment, 24h after treatment, 14d after treatment, muscle strength classification of the limbs. Results 24h after treatment, the sum of muscle strength of the two groups had statistical significance (P <0.05), 500,000 were significantly higher than 250,000. And no bleeding in 2 groups. Conclusions 500,000 U Urokinase is safe and effective in treating progressive cerebral infarction.